Cargando…
A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288759/ http://dx.doi.org/10.1186/2051-1426-2-S3-P85 |
| _version_ | 1782352019388891136 |
|---|---|
| author | Koch, Sven D Hong, Henoch Feyerabend, Susan Retz, Margitta Kuebler, Hubert Heidenreich, Axel van Erps, Thomas Schroeder, Andreas Scheel, Birgit Reus, Valérie Kallen, Karl-Josef Fotin-Mleczek, Mariola Gnad-Vogt, Ulrike Stenzl, Arnulf |
| author_facet | Koch, Sven D Hong, Henoch Feyerabend, Susan Retz, Margitta Kuebler, Hubert Heidenreich, Axel van Erps, Thomas Schroeder, Andreas Scheel, Birgit Reus, Valérie Kallen, Karl-Josef Fotin-Mleczek, Mariola Gnad-Vogt, Ulrike Stenzl, Arnulf |
| author_sort | Koch, Sven D |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288759 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887592015-01-15 A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part Koch, Sven D Hong, Henoch Feyerabend, Susan Retz, Margitta Kuebler, Hubert Heidenreich, Axel van Erps, Thomas Schroeder, Andreas Scheel, Birgit Reus, Valérie Kallen, Karl-Josef Fotin-Mleczek, Mariola Gnad-Vogt, Ulrike Stenzl, Arnulf J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288759/ http://dx.doi.org/10.1186/2051-1426-2-S3-P85 Text en Copyright © 2014 Koch et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Koch, Sven D Hong, Henoch Feyerabend, Susan Retz, Margitta Kuebler, Hubert Heidenreich, Axel van Erps, Thomas Schroeder, Andreas Scheel, Birgit Reus, Valérie Kallen, Karl-Josef Fotin-Mleczek, Mariola Gnad-Vogt, Ulrike Stenzl, Arnulf A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part |
| title | A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part |
| title_full | A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part |
| title_fullStr | A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part |
| title_full_unstemmed | A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part |
| title_short | A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part |
| title_sort | randomized, double-blind, placebo-controlled, phase i/ii trial of rnactive(®)-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the phase i part |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288759/ http://dx.doi.org/10.1186/2051-1426-2-S3-P85 |
| work_keys_str_mv | AT kochsvend arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT honghenoch arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT feyerabendsusan arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT retzmargitta arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT kueblerhubert arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT heidenreichaxel arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT vanerpsthomas arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT schroederandreas arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT scheelbirgit arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT reusvalerie arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT kallenkarljosef arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT fotinmleczekmariola arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT gnadvogtulrike arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT stenzlarnulf arandomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT kochsvend randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT honghenoch randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT feyerabendsusan randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT retzmargitta randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT kueblerhubert randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT heidenreichaxel randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT vanerpsthomas randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT schroederandreas randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT scheelbirgit randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT reusvalerie randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT kallenkarljosef randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT fotinmleczekmariola randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT gnadvogtulrike randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart AT stenzlarnulf randomizeddoubleblindplacebocontrolledphaseiiitrialofrnactivevaccinecv9104inpatientswithmetastaticcastraterefractoryprostatecancermcrpcfirstresultsofthephaseipart |